Key result
Multicap fails to improve 6-month post-MI medication adherence compared to separate pills.
Why the study?
Treatment adherence after MI is poor, and no prior randomized trial evaluating fixed-dose combination therapy had included patients early post-MI.
Does a multicap containing aspirin, atenolol, ramipril, and simvastatin improve adherence at 6 months in patients early after a myocardial infarction?
RCT (n=100)
Open-label
Computer-generated list with block sizes of 4 and 6, stratified by diabetes and gender
No
Does a multicap containing aspirin, atenolol, ramipril, and simvastatin improve adherence at 6 months in patients early after a myocardial infarction?
A multicap strategy containing secondary prevention drugs did not significantly improve treatment adherence at 6 months compared to separate pills in patients early after a myocardial infarction.
Answers are grounded in this paper and cite their sources.
Multicap offers no adherence benefit over separate pills post-MI; challenges polypill expectations in secondary prevention.
Background: Adherence to treatment after a myocardial infarction (MI) is poor, even in the early postinfarction period. Combining evidence-based drugs into a multicap could improve adherence in this population. No previous randomized trial assessing fixed-dose combination therapy has included patients early after a MI. We aimed to assess if a multicap containing four secondary prevention drugs increases adherence to treatment at 6 months after MI hospitalization. The study was designed as a randomized, parallel, open-label, controlled trial. Methods: Patients were randomized within 7 days of a MI to either multicap or control group. The multicap group received a capsule containing aspirin, atenolol, ramipril, and simvastatin. The control group received each drug in separate pills. The primary outcome was adherence at 6 months. We also measured blood pressure, heart rate, serum cholesterol levels, C-reactive protein, and platelet aggregation. Results: The study was stopped prematurely when 100 patients were included for futility. At 6 months, 92 (95.8%) patients were adherent to medical treatment: 98.0% in the multicap group and 93.5% in the control group [relative risk (RR) 1.05; 95% confidence interval (CI) 0.96–1.14; p = 0.347]. There were no differences between groups in systolic blood pressure ( p = 0.662), diastolic blood pressure ( p = 0.784), heart rate ( p = 0.533), total cholesterol ( p = 0.760), LDL-c ( p = 0.979), C-reactive protein ( p = 0.399), or in the proportion of patients with adequate platelet aggregation inhibition ( p = 0.600). Conclusions: The study did not find any improvement in the adherence at 6 months after a MI with a multicap-based strategy (Multicap for Increase Adherence After Acute Myocardial Infarction; [ ClinicalTrials.gov identifier: NCT02271178]).
No takes yet. Share an insight, caveat, or question.
Mariani et al. (2020) conducted an RCT in Acute myocardial infarction (n=100). Multicap (aspirin, atenolol, ramipril, simvastatin) vs. Separate pills of aspirin, atenolol, ramipril, and simvastatin was evaluated on Adherence to medical therapy at 6 months (>80% of pills taken via pill count) (RR 1.05, 95% CI 0.96-1.14, p=0.347). A multicap containing aspirin, atenolol, ramipril, and simvastatin did not improve treatment adherence at 6 months after a myocardial infarction compared to separate pills.
Synapse has enriched 10 related papers. Consider them for comparative context: